-+ 0.00%
-+ 0.00%
-+ 0.00%

ELEVAR THERAPEUTICS: FDA'S DECISION RELATED TO DEFICIENCIES IDENTIFIED DURING A CGMP INSPECTION OF A MANUFACTURING SITE LISTED ON RIVOCERANIB NDA

Reuters·07/10/2026 16:31:13

Please log in to view news